NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

5 equities research analysts have issued 1 year price targets for Aridis Pharmaceuticals' stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $17.40 in the next twelve months. This suggests a possible upside of 151.8% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

Press coverage about ARDS stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aridis Pharmaceuticals earned a news impact score of -3.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aridis Pharmaceuticals.

Aridis Pharmaceuticals saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 41,800 shares, a drop of 21.7% from the January 30th total of 53,400 shares. Based on an average daily volume of 17,500 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.8% of the shares of the stock are short sold. View Aridis Pharmaceuticals' Current Options Chain.

Some companies that are related to Aridis Pharmaceuticals include MEI Pharma (MEIP), Protagonist Therapeutics (PTGX), IVERIC bio (ISEE), Geron (GERN), VBI Vaccines (VBIV), Kala Pharmaceuticals (KALA), XOMA (XOMA), Advanz Pharma (CXRXF), Sol Gel Technologies (SLGL), Theratechnologies (THERF), Aeglea Bio Therapeutics (AGLE), Arcturus Therapeutics (ARCT), Agile Therapeutics (AGRX), Genprex (GNPX) and vTv Therapeutics (VTVT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Gilead Sciences (GILD) and Krystal Biotech (KRYS).

(ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $6.91.

Aridis Pharmaceuticals has a market capitalization of $61.57 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]